Anticoagulation is not associated with an increased risk of variceal bleeding under systemic therapy for advanced HCC.
作者信息
Allaire Manon, Sultanik Philippe, Thabut Dominique
机构信息
AP-HP Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, Service d'Hépato-gastroentérologie, Paris, France.
INSERM UMR 1138, Centre de recherche des Cordeliers, 75006 Paris, France.
出版信息
JHEP Rep. 2024 May 16;6(8):101120. doi: 10.1016/j.jhepr.2024.101120. eCollection 2024 Aug.
Abstract
摘要
相似文献
1
Anticoagulation is not associated with an increased risk of variceal bleeding under systemic therapy for advanced HCC.在晚期肝癌的全身治疗中，抗凝治疗与静脉曲张出血风险增加无关。
JHEP Rep. 2024 May 16;6(8):101120. doi: 10.1016/j.jhepr.2024.101120. eCollection 2024 Aug.
2
Management of varices but not anticoagulation is associated with improved outcome in patients with HCC and macrovascular tumour invasion.对于合并 HCC 和大血管肿瘤侵犯的患者，管理静脉曲张但不抗凝与改善预后相关。
Cancer Imaging. 2024 Jan 13;24(1):9. doi: 10.1186/s40644-024-00657-z.
3
Response to: "Anticoagulation is not associated with an increased risk of variceal bleeding under systemic therapy for advanced HCC".对《在晚期肝癌全身治疗下，抗凝与静脉曲张出血风险增加无关》的回应
JHEP Rep. 2024 Jun 17;6(8):101146. doi: 10.1016/j.jhepr.2024.101146. eCollection 2024 Aug.
4
HCC portal hypertension imaging score derived from CT predicts re-bleeding and mortality after acute variceal bleeding.基于 CT 的 HCC 门脉高压影像学评分可预测急性静脉曲张出血后的再出血和死亡率。
Cancer Imaging. 2024 Mar 28;24(1):45. doi: 10.1186/s40644-024-00689-5.
5
Outcomes of patients with hepatocellular carcinoma presenting with variceal bleeding.出现静脉曲张出血的肝细胞癌患者的预后
Am J Gastroenterol. 2004 Nov;99(11):2158-65. doi: 10.1111/j.1572-0241.2004.40336.x.
6
Anticoagulation therapy early is safe in portal vein thrombosis patients with acute variceal bleeding: a multi-centric randomized controlled trial.早期抗凝治疗对伴有急性静脉曲张出血的门静脉血栓形成患者是安全的：一项多中心随机对照试验。
Intern Emerg Med. 2023 Mar;18(2):513-521. doi: 10.1007/s11739-023-03206-x. Epub 2023 Jan 24.
7
Endoscopic ultrasound-guided cyanoacrylate injection to prevent rebleeding in hepatocellular carcinoma patients with variceal hemorrhage.内镜超声引导下氰基丙烯酸酯注射预防静脉曲张出血的肝细胞癌患者再出血。
J Gastroenterol Hepatol. 2020 Dec;35(12):2192-2201. doi: 10.1111/jgh.15168. Epub 2020 Jul 9.
8
Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study.肝细胞癌门静脉侵犯会加重静脉曲张出血：一项配对巢式病例对照研究。
BMC Cancer. 2021 Jan 5;21(1):11. doi: 10.1186/s12885-020-07708-1.
9
Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly Diagnosed Hepatocellular Carcinoma.原发性静脉曲张出血的一级预防与新诊断肝细胞癌患者生存率的提高
Dig Dis Sci. 2016 Nov;61(11):3354-3362. doi: 10.1007/s10620-016-4255-6. Epub 2016 Jul 19.
10
Prevention of variceal rebleeding in cirrhotic patients with advanced hepatocellular carcinoma receiving molecularly targeted therapy: a randomized pilot study of transjugular intrahepatic portosystemic shunt versus endoscopic plus β-blocker.预防接受分子靶向治疗的晚期肝细胞癌肝硬化患者的静脉曲张再出血：经颈静脉肝内门体分流术与内镜加β受体阻滞剂的随机试点研究。
Hepatol Int. 2022 Dec;16(6):1379-1389. doi: 10.1007/s12072-022-10388-7. Epub 2022 Oct 18.
引用本文的文献
1
Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy.肝细胞癌中的免疫微环境：从发病机制到免疫治疗
Cell Mol Immunol. 2025 Jun 11. doi: 10.1038/s41423-025-01308-4.
2
Response to: "Anticoagulation is not associated with an increased risk of variceal bleeding under systemic therapy for advanced HCC".对《在晚期肝癌全身治疗下，抗凝与静脉曲张出血风险增加无关》的回应
JHEP Rep. 2024 Jun 17;6(8):101146. doi: 10.1016/j.jhepr.2024.101146. eCollection 2024 Aug.
本文引用的文献
1
Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.阿替利珠单抗/贝伐珠单抗或乐伐替尼治疗肝细胞癌：聚焦出血和血栓栓塞事件的多中心真实世界研究
JHEP Rep. 2024 Apr 8;6(6):101065. doi: 10.1016/j.jhepr.2024.101065. eCollection 2024 Jun.
2
Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab.血管内皮生长因子（VEGF）通路抑制剂联合免疫检查点抑制剂（ICI）在晚期肝细胞癌（HCC）的治疗中取得了较好的疗效。然而，血管内皮生长因子（VEGF）通路抑制剂联合免疫检查点抑制剂（ICI）在伴有门静脉高压（PH）的 HCC 患者中的疗效尚不清楚。
Dig Liver Dis. 2024 Sep;56(9):1621-1630. doi: 10.1016/j.dld.2024.02.018. Epub 2024 Mar 27.
3
Baveno VI and VII criteria are not suitable for screening for large varices or clinically significant portal hypertension in patients with hepatocellular carcinoma.Baveno VI 和 VII 标准不适用于筛查肝细胞癌患者的大静脉曲张或临床显著门静脉高压。
Aliment Pharmacol Ther. 2023 Aug;58(3):346-356. doi: 10.1111/apt.17599. Epub 2023 Jun 9.
4
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.美国肝病研究学会肝细胞癌预防、诊断和治疗实践指南。
Hepatology. 2023 Dec 1;78(6):1922-1965. doi: 10.1097/HEP.0000000000000466. Epub 2023 May 22.
5
Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management.肝癌患者的门静脉高压症和静脉曲张出血：预防与管理方面的证据空白
Hepatology. 2024 Jan 1;79(1):213-223. doi: 10.1097/HEP.0000000000000291. Epub 2023 Jan 13.
6
Baveno VII - Renewing consensus in portal hypertension.《巴韦诺 VII 共识：门静脉高压领域的新共识》
J Hepatol. 2022 Apr;76(4):959-974. doi: 10.1016/j.jhep.2021.12.022. Epub 2021 Dec 30.
7
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
Zotero 插件